Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 31: 1185-1188, 1985;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ito, S.
Right arrow Articles by Fujita, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ito, S.
Right arrow Articles by Fujita, K.

Clinical Chemistry, Vol 31, 1185-1188, Copyright © 1985 by American Association for Clinical Chemistry

"Total" acidic metabolites of catecholamines in urine as determined by hydrolysis with hydriodic acid and liquid chromatography: application to patients with neuroblastoma and melanoma

S Ito, T Kato, K Maruta, K Jimbow and K Fujita

We describe a method for determining the "total" excretion of acidic metabolites of catecholamines by measuring 3,4-dihydroxyphenylacetic acid (DOPAC) formed by hydriodic acid hydrolysis of 4-hydroxy-3- methoxyphenylacetic acid (HVA), 4-hydroxy-3-methoxymandelic acid (VMA), and their conjugates. The DOPAC in the diluted hydrolysate is measured directly by liquid chromatography with electrochemical detection. Normal values, expressed in relation to excretion of creatinine, vary as a function of age. For healthy subjects, the mean DOPAC value after hydrolysis was 1.15 times that for unconjugated HVA, VMA, and DOPAC combined. Preliminary results for patients with neuroblastoma and melanoma indicate the potential usefulness of the method for diagnosis and prognosis of patients with neural crest tumors that produce dopa or catecholamines.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1985 by the American Association for Clinical Chemistry.